Showing results (81-90 of 142) with videos related to

Sort By:
Pageof 15
Blood|June 16, 2012
Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosisTiziano Barbui, Jürgen Thiele, Alessandra Carobbio, et al.
American Journal of Hematology|September 3, 2013
Masked polycythemia vera (mPV): results of an international studyTiziano Barbui, Jürgen Thiele, Heinz Gisslinger, et al.
Blood|April 15, 2011
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patientsAlessandra Carobbio, Juergen Thiele, Francesco Passamonti, et al.
Wiener Klinische Wochenschrift|September 17, 2015
Iron metabolism and iron supplementation in cancer patientsHeinz Ludwig, Rayko Evstatiev, Gabriela Kornek, et al.
Blood|December 9, 2004
Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational studyGuido Finazzi, Vanesa Caruso, Roberto Marchioli, et al.
Blood|January 21, 2014
Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohortsFrancesco Passamonti, Margherita Maffioli, Francisco Cervantes, et al.
Blood|July 5, 2005
Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET)Giovanni Barosi, Dominique Bordessoule, Jean Briere, et al.
Blood Cancer Journal|August 6, 2025
Neutrophil-to-Lymphocyte ratio as surrogate for JAK2<sup>V617F</sup> suppression and event-free survival in polycythemia veraTiziano Barbui, Arianna Ghirardi, Victoria Empson, et al.
The Lancet. Haematology|March 31, 2022
Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendationsMonia Marchetti, Alessandro Maria Vannucchi, Martin Griesshammer, et al.
Blood|November 1, 2013
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosisFrancisco Cervantes, Alessandro M Vannucchi, Jean-Jacques Kiladjian, et al.
Pageof 15